CFT8634是一种口服活性的BRD9靶向降解剂，用于滑膜肉瘤和SMARCB1缺失实体瘤的研究。

FHD-609是一种 BRD9 抑制剂和降解剂，靶向 ncBAF，用于多种癌症研究。

PROTAC BRD9 Degrader-1 is a PROTAC targeting on BRD9, consist of a BRD9 bromodomain probe I-BRD9 as a warhead ligand and pomalidomide as the CRBN ligand.